-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $39

Benzinga·11/10/2026 15:05:59
Listen to the news
Wells Fargo analyst Derek Archila maintains Viridian Therapeutics (NASDAQ:VRDN) with a Overweight and raises the price target from $34 to $39.